Insight

May 6, 2024, 07:29

Center for Cancer Immune Therapy – Molecular patterns of resistance to immune checkpoint blockade in melanoma

Center for Cancer Immune Therapy shared on LinkedIn:

“Molecular patterns of resistance to immune checkpoint blockade in melanoma.

Free access at Nature Communications (9 April 2024)

Key findings:

Molecular mechanisms explaining resistance may differ depending on immune checkpoint blockade (ICB) regimen,
PD1-resistant melanomas have few T cells, and in particular PD1+ tumor-reactive T cells,
Tertiary lymphoid structures are rare in ICB resistant melanomas.

Take home:

This study highlights the complexity of development of ICB resistance in melanoma.

Why it matters:

Understanding molecular mechanisms underlying ICB resistance can help identify new immunotherapeutic targets for patients in high need of treatment.

This study was conducted primarily at Lund University (group of Göran Jönsson) in close collaboration with Center for Cancer Immune Therapy (groups of Inge Marie Svane and Marco Donia).”

Source: Center for Cancer Immune Therapy/LinkedIn

Ana Carneiro Anna Ebbesson Bengt Phung cancer CCIT Center for Cancer Immune Therapy Christian Ingvar Göran Jönsson Immune checkpoint blockade Inge Marie Svane Ingrid Hedenfalk Joan Yuan Kamila Kamińska Kari Nielsen Karolin Isaksson Katja Harbst Kristian Pietras Lund University Marco Donia Martin Lauss Melanoma Nature Communications OncoDaily Oncology PD1 resistancy Troels Holz Borch

Esophageal Cancer: Symptoms, Causes, Stages, Diagnosis & Treatment

Faster, Flexible and Affordable: Mikhail Groubman on Building a Global Legacy in Clinical Research in an Untapped Market

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Special Coverage